메뉴 건너뛰기




Volumn 82, Issue 24, 2014, Pages 2158-2164

Accelerated lymphocyte recovery after alemtuzumab does not predict multiple sclerosis activity

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CD19 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN;

EID: 84903985522     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000520     Document Type: Article
Times cited : (47)

References (14)
  • 1
    • 54949143968 scopus 로고    scopus 로고
    • Alemtuzumab vs. Interferon beta-1a in early multiple sclerosis
    • Coles AJ, Compston DA, Selmaj KW, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008;359: 1786-1801.
    • (2008) N Engl J Med , vol.359 , pp. 1786-1801
    • Coles, A.J.1    Compston, D.A.2    Selmaj, K.W.3
  • 2
    • 84869492471 scopus 로고    scopus 로고
    • Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial
    • Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380: 1819-1828.
    • (2012) Lancet , vol.380 , pp. 1819-1828
    • Cohen, J.A.1    Coles, A.J.2    Arnold, D.L.3
  • 3
    • 84869507357 scopus 로고    scopus 로고
    • Alemtuzumab for patients with relapsing multiple sclerosis after diseasemodifying therapy: A randomised controlled phase 3 trial
    • Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after diseasemodifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380: 1829-1839.
    • (2012) Lancet , vol.380 , pp. 1829-1839
    • Coles, A.J.1    Twyman, C.L.2    Arnold, D.L.3
  • 5
    • 84857055778 scopus 로고    scopus 로고
    • Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis
    • Hill-Cawthorne GA, Button T, Tuohy O, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry 2012; 83: 298-304.
    • (2012) J Neurol Neurosurg Psychiatry , vol.83 , pp. 298-304
    • Hill-Cawthorne, G.A.1    Button, T.2    Tuohy, O.3
  • 6
    • 84860780657 scopus 로고    scopus 로고
    • Alemtuzumab more effective than interferon-1a at 5-year follow-up of camms223 clinical trial
    • Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012;78: 1069-1078.
    • (2012) Neurology , vol.78 , pp. 1069-1078
    • Coles, A.J.1    Fox, E.2    Vladic, A.3
  • 7
    • 84890285333 scopus 로고    scopus 로고
    • Human autoimmunity after lymphocyte depletion is caused by homeostatic t-cell proliferation
    • Jones JL, Thompson SA, Loh P, et al. Human autoimmunity after lymphocyte depletion is caused by homeostatic T-cell proliferation. Proc Natl Acad Sci USA 2013;110: 20200-20205.
    • (2013) Proc Natl Acad Sci USA , vol.110 , pp. 20200-20205
    • Jones, J.L.1    Thompson, S.A.2    Loh, P.3
  • 8
    • 84873690365 scopus 로고    scopus 로고
    • Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis
    • Cossburn MD, Harding K, Ingram G, et al. Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology 2013;80: 55-61.
    • (2013) Neurology , vol.80 , pp. 55-61
    • Cossburn, M.D.1    Harding, K.2    Ingram, G.3
  • 10
    • 84863304598 scopus 로고    scopus 로고
    • R Core Team. Vienna Austria: R Foundation For Statistical Computing; 2013. Available at. Accessed August 16
    • R Core Team. R: A Language and environment for statistical computing [computer program]. Vienna, Austria: R Foundation for Statistical Computing; 2013. Available at: http://www.R-project.org/. Accessed August 16, 2013.
    • (2013) R: A Language And Environment For Statistical Computing [Computer Program]
  • 11
    • 31544467633 scopus 로고    scopus 로고
    • The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy
    • Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006;253: 98-108.
    • (2006) J Neurol , vol.253 , pp. 98-108
    • Coles, A.J.1    Cox, A.2    Le Page, E.3
  • 12
    • 0032882173 scopus 로고    scopus 로고
    • Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
    • Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46: 296-304.
    • (1999) Ann Neurol , vol.46 , pp. 296-304
    • Coles, A.J.1    Wing, M.G.2    Molyneux, P.3
  • 13
    • 0030880011 scopus 로고    scopus 로고
    • Treatment of multiple sclerosis with the monoclonal anti-cd4 antibody cm-T412: Results of a randomized, double-blind, placebo-controlled, mr-monitored phase ii trial
    • van Oosten BW, Hodgkinson S, Barkhof F, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 1997;49: 351-357.
    • (1997) Neurology , vol.49 , pp. 351-357
    • Van Oosten, B.W.1    Hodgkinson, S.2    Barkhof, F.3
  • 14
    • 27944439639 scopus 로고    scopus 로고
    • Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis
    • Cox AL, Thompson SA, Jones JL, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol 2005;35: 3332-3342.
    • (2005) Eur J Immunol , vol.35 , pp. 3332-3342
    • Cox, A.L.1    Thompson, S.A.2    Jones, J.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.